ECO Animal Health Group
plc
("ECO" or
the "Company")
Appointment of Dr. Joachim Hasenmaier
as Non-Executive
Director
ECO
Animal Health Group plc (AIM: EAH), a rapidly growing global
animal health company with a portfolio of marketed veterinary
products and a maturing proprietary R&D pipeline,
announces the appointment of Dr. Joachim Hasenmaier as a
Non-Executive Director, with immediate effect.
Dr. Hasenmaier is a highly experienced commercial
leader with more than two decades in the international animal
health industry. From 2001 to 2019 he held a variety of senior
roles within the animal health division at Boehringer Ingelheim,
concluding as member of the Board of Managing Directors
responsible for the entire animal health division. During
this time he led successful transformation initiatives including
the integration of the former Sanofi animal health business Merial,
spearheaded key product launches and supported rapid global growth
and expansion.
Dr. Andrew Jones,
Chairman of ECO, commented: "On behalf of the Board, I am
delighted to welcome Joachim as a Non-Executive Director to ECO. He
has a wealth of sector and board experience, and I am confident
that his strong track record of delivering sales growth and driving
performance will be hugely beneficial to the growth of the Company.
We are excited about what 2024 holds as we look to maximise the
potential of our broad commercial and R&D portfolio and expand
our business both organically and via new opportunities."
Dr. Joachim
Hasenmaier, incoming Non-Executive Director of ECO, added:
"ECO Animal Health is at a pivotal time in its development. The
Company is well positioned to capitalise on the future growth
opportunities offered by its innovative, focused pipeline of
vaccines and biologics. I look forward to working closely with the
Board to drive the next phase of growth as a sector-leading pioneer
in animal health."
Dr. Hasenmaier has also served as Chairman of the
Board at IMV Technologies since 2022 and as a Member of the
Supervisory Boards of Invetx. He served on the Board of
NASDAQ-listed Heska prior to its acquisition by Mars Petcare. He
also held senior positions at Hoechst Roussel Vet and McKinsey
& Company.
Dr. Hasenmaier is a Doctor of Veterinary Medicine and
holds a PhD in Immunology from Ludwig-Maximillians University in
Munich. has an MBA from Northwestern University, USA.
Additional
Information on the Board Appointment
The following additional information is provided with
regards to the appointment of Joachim Alfred Hasenmaier, aged 64,
in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules
for Companies:
Current
directorships/partnerships:
· Invetx,
Inc.
· Minotaur
Invest (holding company for IMV Technologies)
· Phagelux
Agrihealth
Directorships/partnerships within the last five
years:
·
Heska Corporation
·
Boehringer Ingelheim Corporate Center
GMBH
·
Boehringer AG
·
Boehringer Ingelheim GMBH
·
C.H. Boehringer Sohn AG & Co. KG
·
Profunda Verwaltungsgesellschaft MBH & Co
KG
·
Boehringer Ingelheim Deutschland GMBH
·
Boehringer Ingelheim Vetmedica GMBH
·
Boehringer Ingelheim International GMBH
·
Boehringer Ingelheim Verwaltungs GMBH
·
Boehringer Ingelheim Auslandsbeteiligungs
GMBH
There are no further disclosures required to be made
in respect of the appointment under AIM Rule 17 and Schedule 2(g)
of the AIM Rules for Companies.
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices
including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a proprietary,
patented medication which is effective against both respiratory and
intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com